Paratek Pharmaceuticals Q3 EPS $(1) Beats $(1.05) Estimate, Sales $3.1M Miss $3.9M Estimate

Paratek Pharmaceuticals (NASDAQ:PRTK) reported quarterly losses of $(1) per share which beat the analyst consensus estimate of $(1.05) by 4.76 percent. This is a 0.99 percent increase over losses of $(1.01) per share

Benzinga · 11/12/2019 21:17

Paratek Pharmaceuticals (NASDAQ:PRTK) reported quarterly losses of $(1) per share which beat the analyst consensus estimate of $(1.05) by 4.76 percent. This is a 0.99 percent increase over losses of $(1.01) per share from the same period last year. The company reported quarterly sales of $3.1 million which missed the analyst consensus estimate of $3.9 million by 20.51 percent. This is a 6.10K percent increase over sales of $50 thousand the same period last year.